CSF NFL levels, reflecting neuroaxonal damage, are currently used as biomarkers of response to therapy and prognosis in several inflammatory diseases, neurodegenerative diseases, traumatic brain injury, cerebrovascular disease, and MS (47). The gene discussed is NEFL; the disease is neurodegenerative disease.